Tools

LEADER 02593cam 2200529 a 4500

001 ocm24603103;

003 OCoLC;

005 20160802101829.0;

008 920108s1991 dcu b f000 0 eng c;

010 a| 91601788;

020 a| 0160354927;

020 a| 9780160354922;

020 a| 0160354935;

020 a| 9780160354939;

029 1 a| AU@b| 000008649667;

035 a| (Sirsi) o24603103;

035 a| (OCoLC)24603103;

043 a| n-us---;

049 a| ERE#;

050 00 a| KF26b| .J835 1991;

074 a| 1042-A, 1042-B (MF);

082 00 a| 363.19/42| 20;

086 0 a| Y 4.J 89/2:S.HRG.102-175;

245 10 a| Marketing of Clozaril :b| improved safety or barrier to access : hearing before the Subcommittee on Antitrust, Monopolies and Business Rights of the Committee on the Judiciary, United States Senate, One Hundred Second Congress, first session, on the marketing of Clozaril, a drug for the treatment of schizophrenia, March 5, 1991.;

260 a| Washington :b| U.S. G.P.O. :b| For sale by the U.S. G.P.O., Supt. of Docs., Congressional Sales Office,c| 1991.;

300 a| iii, 139 pages ;c| 24 cm.;

336 a| textb| txt2| rdacontent;

337 a| unmediatedb| n2| rdamedia;

338 a| volumeb| nc2| rdacarrier;

490 1 a| S. hrg. ;v| 102-175;

500 a| "Serial no. J-102-6.";

504 a| Includes bibliographical references.;

650 0 a| Clozapinex| Marketing.=| ^A1017395;

650 0 a| Drugsx| Pricesz| United States.=| ^A30023;

650 0 a| Medical carez| United Statesx| Cost control.=| ^A5172;

610 20 a| Sandoz Pharmaceuticals Corporation.=| ^A1290221;

650 0 a| Drug accessibilityz| United States.=| ^A1113855;

776 08 i| Online version:a| United States. Congress. Senate. Committee on the Judiciary. Subcommittee on Antitrust, Monopolies, and Business Rights.t| Marketing of Clozaril.d| Washington : U.S.G.P.O. : For sale by the U.S.G.P.O., Supt. of Docs., Congressional Sales Office, 1991w| (OCoLC)657464609;

810 1 a| United States.b| Congress.b| Senate.t| S. hrg. ;v| 102-175.=| ^A500722;

938 a| Baker and Taylorb| BTCPn| 91601788;

994 a| C0b| ERE;

596 a| 1;

998 a| 4433707;

999 a| Y 4.J 89/2:S.HRG.102-175w| SUDOCc| 1i| 30372016977727l| JDOSm| JOYNERr| Ys| Yt| JDOSBKu| 6/21/2016x| BOOKz| JFEDDOCSo| .STAFF. jmpl;

Marketing of Clozaril : improved safety or barrier to access : hearing before the Subcommittee on Antitrust, Monopolies and Business Rights of the Committee on the Judiciary, United States Senate, One Hundred Second Congress, first session, on the marketing of Clozaril, a drug for the treatment of schizophrenia, March 5, 1991.

Author/creator	United States
Format	Book
Publication Info	Washington : U.S. G.P.O. : For sale by the U.S. G.P.O., Supt. of Docs., Congressional Sales Office, 1991.
Description	iii, 139 pages ; 24 cm.
Subjects	Sandoz Pharmaceuticals Corporation. Clozapine--Marketing. Drugs--Prices. --United States. Medical care--United States. --Cost control. Drug accessibility--United States.

Series	S. hrg. ; 102-175 United States. Congress. Senate. S. hrg. ; 102-175. ^A500722
General note	"Serial no. J-102-6."
Bibliography note	Includes bibliographical references.
Issued in other form	Online version: United States. Congress. Senate. Committee on the Judiciary. Subcommittee on Antitrust, Monopolies, and Business Rights. Marketing of Clozaril. Washington : U.S.G.P.O. : For sale by the U.S.G.P.O., Supt. of Docs., Congressional Sales Office, 1991
LCCN	91601788
ISBN	0160354927
ISBN	9780160354922
ISBN	0160354935
ISBN	9780160354939
GPO item number	1042-A, 1042-B (MF)
Govt. docs number	Y 4.J 89/2:S.HRG.102-175

Click here for more information about this title